Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
RELX 
Relx PLC ADR (RELX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/11/2025: RELX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $56.45
1 Year Target Price $56.45
| 1 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 17.91% | Avg. Invested days 53 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 12/11/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 72.89B USD | Price to earnings Ratio 29.26 | 1Y Target Price 56.45 |
Price to earnings Ratio 29.26 | 1Y Target Price 56.45 | ||
Volume (30-day avg) 2 | Beta 0.28 | 52 Weeks Range 39.31 - 56.03 | Updated Date 12/11/2025 |
52 Weeks Range 39.31 - 56.03 | Updated Date 12/11/2025 | ||
Dividends yield (FY) 1.63% | Basic EPS (TTM) 1.37 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 20.19% | Operating Margin (TTM) 30.86% |
Management Effectiveness
Return on Assets (TTM) 12.38% | Return on Equity (TTM) 72.05% |
Valuation
Trailing PE 29.26 | Forward PE 21.23 | Enterprise Value 82435206752 | Price to Sales(TTM) 7.65 |
Enterprise Value 82435206752 | Price to Sales(TTM) 7.65 | ||
Enterprise Value to Revenue 6.5 | Enterprise Value to EBITDA 17.26 | Shares Outstanding 1818571317 | Shares Floating 1816834194 |
Shares Outstanding 1818571317 | Shares Floating 1816834194 | ||
Percent Insiders - | Percent Institutions 4.54 |
Upturn AI SWOT
Relx PLC ADR
Company Overview
History and Background
Relx PLC (formerly Reed Elsevier) was formed in 1993 through the merger of Reed International of the UK and Elsevier of the Netherlands. It is a global provider of information and analytics. The company has undergone significant transformation, shifting from traditional publishing to a data analytics and decision-tools company, with a strong focus on scientific, technical, medical, and legal information. The ADR (American Depositary Receipt) represents ordinary shares of Relx PLC traded on U.S. stock exchanges.
Core Business Areas
- Scientific, Technical & Medical (STM) Solutions: Provides scientific literature, data, and analytics to researchers, healthcare professionals, and institutions to advance scientific discovery and improve patient care. This includes databases like Scopus and tools for drug development.
- Risk & Analytics Solutions: Offers data and analytics to help customers make better decisions in areas such as fraud detection, identity verification, and credit risk assessment for financial services, insurance, and government sectors.
- Legal & Regulatory Solutions: Delivers legal information, analytics, and workflow tools to legal professionals, corporations, and government agencies, aiding in research, compliance, and case management.
- Exhibitions: Organizes and operates a portfolio of global exhibitions and conferences, facilitating business connections and knowledge sharing across various industries.
Leadership and Structure
Relx PLC is led by a Chief Executive Officer and a Board of Directors. The company operates through its distinct business segments, each with its own management team responsible for strategy and operations within their respective domains. The specific names and roles of current leadership can be found on the company's official investor relations website.
Top Products and Market Share
Key Offerings
- Scopus: A large abstract and citation database of peer-reviewed literature: scientific journals, books and conference proceedings. It is a key tool for researchers. Competitors include Web of Science (Clarivate Analytics).
- LexisNexis Risk Solutions: Provides data and analytics for risk management, fraud prevention, identity verification, and regulatory compliance. Competitors include Equifax, TransUnion, and Experian in certain segments.
- LexisNexis Legal & Professional: Offers legal research platforms, analytics, and workflow solutions for legal professionals. Competitors include Thomson Reuters (Westlaw) and Bloomberg Law.
- Elsevier Clinical Solutions: Provides clinical decision support tools, drug information, and health reference data for healthcare professionals. Competitors include Wolters Kluwer and smaller specialized providers.
Market Dynamics
Industry Overview
Relx operates in industries characterized by the increasing demand for data, analytics, and specialized information. The scientific and medical information sector is driven by research and development activity and the need for efficient dissemination of knowledge. The risk and analytics sector is growing due to increasing regulatory scrutiny, the need for fraud prevention, and the rise of big data. The legal information sector is evolving with the demand for digital solutions and efficiency tools.
Positioning
Relx is a leading provider of information and analytics, leveraging its deep domain expertise and proprietary data assets. Its competitive advantages lie in its established brands, broad customer base, recurring revenue models, and continuous investment in technology and data science. The company's strategic shift towards data analytics and decision tools has strengthened its position in high-growth segments.
Total Addressable Market (TAM)
The TAM for Relx's various segments is substantial and growing, encompassing global markets for scientific research, healthcare information, risk management, identity verification, and legal services. The company is well-positioned to capture a significant share of this TAM due to its diversified offerings and global reach.
Upturn SWOT Analysis
Strengths
- Strong brand recognition and established market positions in key segments.
- Diversified revenue streams across multiple industries.
- Significant investment in data analytics and technology.
- Recurring revenue models providing stability.
- Global presence and extensive customer base.
Weaknesses
- Potential for disruption from emerging technologies.
- Reliance on intellectual property and data access.
- Competition from agile, specialized tech companies.
- Complex organizational structure due to diverse segments.
Opportunities
- Expansion of data analytics capabilities in emerging markets.
- Growth in AI and machine learning applications for decision support.
- Further integration of services across segments.
- Acquisitions to enhance technological capabilities or market reach.
- Increasing demand for regulatory compliance and risk management solutions.
Threats
- Data privacy regulations and cybersecurity risks.
- Economic downturns impacting customer spending.
- Intensifying competition and pricing pressures.
- Changes in academic publishing models.
- Geopolitical instability affecting global operations.
Competitors and Market Share
Key Competitors
- Thomson Reuters (TRI)
- Clarivate PLC (CLVT)
- Moody's Corporation (MCO)
- S&P Global Inc. (SPGI)
- Wolters Kluwer (WOLKFY)
Competitive Landscape
Relx benefits from its established brand, deep domain expertise, and diversified revenue model. Its primary advantage lies in its integrated data and analytics platforms that offer significant value to professional customers. However, it faces competition from agile tech companies and specialized data providers who may offer niche solutions or disrupt existing models. The ability to continuously innovate and adapt to evolving customer needs is crucial.
Major Acquisitions
Nota
- Year: 2024
- Acquisition Price (USD millions): 275
- Strategic Rationale: Enhances LexisNexis's capabilities in legal research and drafting, particularly in AI-powered tools for contract analysis and generation.
LenderKit
- Year: 2023
- Acquisition Price (USD millions):
- Strategic Rationale: Strengthens LexisNexis Risk Solutions' offering for financial institutions by providing advanced loan origination and management tools.
HealthStream's Provider Solutions Business
- Year: 2023
- Acquisition Price (USD millions):
- Strategic Rationale: Expands Elsevier's clinical solutions by adding a robust platform for provider data management and credentialing.
Growth Trajectory and Initiatives
Historical Growth: Relx has achieved significant growth by strategically transforming its business model from traditional publishing to a data analytics and decision-tools provider. Its historical growth has been characterized by organic expansion within its core segments and strategic acquisitions to bolster its capabilities.
Future Projections: Analyst expectations for Relx's future growth are generally positive, driven by continued demand for data and analytics, especially in the risk, legal, and scientific domains. Projections often highlight the company's ability to leverage its existing platforms and expand into new data-driven services.
Recent Initiatives: Recent initiatives have focused on enhancing its AI and machine learning capabilities, expanding its digital platforms, and continuing to integrate its offerings to provide more comprehensive solutions to customers. Acquisitions have also played a role in strengthening its strategic positioning.
Summary
Relx PLC ADR is a robust information and analytics company with a strong market position in scientific, legal, and risk solutions. Its strategic shift to data-driven services and continuous investment in technology have fueled consistent growth and profitability. While facing competition and evolving market dynamics, Relx's diversified model and strong execution make it a resilient player. Key areas to monitor include data privacy, technological disruption, and continued expansion in high-growth segments.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Relx PLC Investor Relations Website
- Company Financial Reports (Annual and Quarterly)
- Reputable Financial News and Analysis Platforms (e.g., Bloomberg, Refinitiv, Wall Street Journal)
Disclaimers:
This JSON output is for informational purposes only and should not be considered financial advice. Market share data is estimated and can fluctuate. Acquisition prices may not always be publicly disclosed or may represent a range. Historical financial performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Relx PLC ADR
Exchange NYSE | Headquaters - | ||
IPO Launch date 1994-10-07 | CEO & Executive Director Mr. Erik Engstrom M.Sc Econ, M.Sc Eng., MBA | ||
Sector Industrials | Industry Specialty Business Services | Full time employees 36000 | Website https://www.relx.com |
Full time employees 36000 | Website https://www.relx.com | ||
RELX PLC, together with its subsidiaries, provides information-based analytics and decision tools for professional and business customers in North America, Europe, and internationally. It operates through four segments: Risk; Scientific, Technical & Medical; Legal; and Exhibitions. The Risk segment offers information-based analytics and decision tools that combine public and industry specific content with technology and algorithms to assist clients in evaluating and predicting risk. The Scientific, Technical & Medical segment provides scientific and medical information and data sets that help researchers and healthcare professionals to advance science and health outcomes. The Legal segment provides legal, regulatory, and business information and analytics that help customers in decision-making, as well as increases the productivity. The Exhibitions segment is involved in the business that combines face-to-face with data and digital tools to help customers learn about markets, source products, and transactions. The company was formerly known as Reed Elsevier PLC and changed its name to RELX PLC in July 2015. RELX PLC was incorporated in 1903 and is headquartered in London, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.